Aprea Therapeutics Inc (APRE)
4.705
+0.10
(+2.13%)
USD |
NASDAQ |
May 31, 16:00
4.55
-0.16
(-3.29%)
After-Hours: 20:00
Aprea Therapeutics Cash from Operations (TTM): -13.13M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -13.13M |
December 31, 2023 | -12.18M |
September 30, 2023 | -12.46M |
June 30, 2023 | -16.81M |
March 31, 2023 | -22.49M |
December 31, 2022 | -25.01M |
September 30, 2022 | -31.17M |
June 30, 2022 | -32.81M |
March 31, 2022 | -31.66M |
Date | Value |
---|---|
December 31, 2021 | -37.69M |
September 30, 2021 | -40.71M |
June 30, 2021 | -43.90M |
March 31, 2021 | -45.78M |
December 31, 2020 | -41.80M |
September 30, 2020 | -43.35M |
June 30, 2020 | -34.72M |
March 31, 2020 | -30.05M |
December 31, 2019 | -26.71M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-45.78M
Minimum
Mar 2021
-12.18M
Maximum
Dec 2023
-30.13M
Average
-31.41M
Median
Cash from Operations (TTM) Benchmarks
NeuBase Therapeutics Inc (DELISTED) | -14.78M |
Stoke Therapeutics Inc | -84.28M |
NovaBay Pharmaceuticals Inc | -4.516M |
Palatin Technologies Inc | -33.74M |
iBio Inc | -18.67M |